NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

NewAmsterdam Pharma (NAMS) reported Q2 2025 GAAP revenue of $19.1 million, significantly exceeding consensus by 49.6% primarily due to a $16.1 million milestone payment from its Menarini partnership. While R&D expenses declined 28.4% as late-stage trials wound down, SG&A costs rose 65.5% reflecting increased commercial investment ahead of potential product launch. The company narrowed its net loss to $17.4 million and maintained a robust cash position of $783.3 million. Clinically, obicetrapib demonstrated positive new data, including a 20.5% reduction in an Alzheimer's biomarker in high-risk patients, alongside consistent LDL-C lowering, with its European marketing authorization application on track for 2H 2025, positioning regulatory milestones and commercial buildout as key future catalysts.

Analysis

NewAmsterdam Pharma (NAMS) reported a strong Q2 2025, characterized by a significant strategic pivot from late-stage development toward commercial readiness. The company's GAAP revenue of $19.1 million, which beat consensus by 49.6%, was driven entirely by a $16.1 million milestone payment from its Menarini partnership, underscoring its pre-commercial status. This revenue recognition, combined with a 28.4% year-over-year decline in R&D expenses as clinical trials wind down, contributed to a substantial narrowing of the net loss to $17.4 million from $39.0 million a year prior. Conversely, a 65.5% year-over-year increase in SG&A expenses reflects aggressive investment in building out commercial infrastructure. The company maintains a robust cash position of $783.3 million to fund these activities. Clinically, the narrative was bolstered by new data showing obicetrapib reduced the Alzheimer's biomarker p-tau217 by 20.5% in high-risk patients, potentially expanding its therapeutic scope beyond its primary LDL-C lowering indication. With a European marketing application on track for 2H 2025, the company's near-term valuation hinges on upcoming regulatory milestones and the pivotal PREVAIL cardiovascular outcomes trial.

Key Decisions for Investors

• Investors should recognize NAMS is in a transitional phase, where rising SG&A expenses are a key indicator of progress toward commercialization; monitor this spending relative to the European marketing application timeline expected in 2H 2025.
• The stock's performance is highly dependent on future catalysts, primarily the PREVAIL trial results, creating a binary risk profile that warrants careful position sizing according to individual risk tolerance.
• While the core investment thesis rests on cardiovascular disease, the positive data on an Alzheimer's biomarker introduces a significant long-term optionality that should be monitored for further clinical validation.
• Given the increasing cash burn from pre-commercial activities, it is crucial to track the adequacy of the $783.3 million cash reserve to ensure it provides a sufficient runway through key regulatory and clinical milestones without near-term dilutive financing.